The impact of new diagnosis and treatment for minimally invasive lung cancer


The impact of new diagnosis and treatment for minimally invasive lung cancer

diagnosis and treatment, lung cancer

Elize Sturkenboom – van de Wetering, Venture Leader of Lung Oncology at Phillips Healthcare, discusses the diagnosis and treatment of lung cancer with a new minimally invasive therapy

Lung cancer kills around 1.8 million people a year worldwide. It is the leading cause of cancer death worldwide1, leading to greater loss of life than breast, colon and prostate cancer combined. Although early diagnosis and treatment are essential for better outcomes and improved quality of life, the majority of lung cancers are currently diagnosed too late, with minimal chance of surgical cure. Only 21% of all people diagnosed with lung cancer will survive 5 years or more. When lung cancer patients are diagnosed early and treated immediately, a patient’s chance of surviving at 10 years jumps to 92%2.

New hope on the horizon for lung cancer screening

Changes in health policies and government involvement have increased lung cancer screening. The implementation of lung cancer screening programs with low-dose CT scans is driving a shift resulting in more patients with curable lesions.

This comes with its own challenges. Small peripheral nodules are generally more complex to reach and locate during biopsy and surgery. The good news is that more and more doctors are adopting new techniques to diagnose and then treat these small lesions that are so difficult to detect.

The impact of new image guidance technology on early diagnosis and treatment

Increasingly precise and less invasive methods are introduced and adopted in clinical practice and have ushered in a new era. Nowadays, even barely visible nodules of only 8 mm can be diagnosed and treated with new minimally invasive techniques. Advanced imaging integrated in operating theaters and bronchoscopy rooms can be combined with navigational bronchoscopy to achieve high-accuracy diagnosis and meet the need to combine diagnosis and staging with minimally invasive therapy in a single room.

“Cone-beam computed tomography is the critical step towards targeting nodules smaller than 20 mm and an essential tool for transitioning to bronchoscopic microwave ablation of peripheral lung lesions,” said Professor Shah Pallav, MD , consultant pulmonologist at the Royal Brompton Hospital in London. , UK.

Diagnosis of small peripheral lung lesions

Recently, Radboud University Medical Center (Radboudumc), a leading university and teaching hospital in the Netherlands (Nijmegen, Netherlands), announced positive results from a clinical study aimed at setting a new safety standard and accuracy in the diagnosis of small lung lesions. Study Reaches New Milestone with 90% Diagnostic Accuracy of Lung Nodules Suspicious of Cancer Using Philips Lung Suite Technology Combined with Company’s Image-Guided Therapy System – Azurion for Procedures bronchoscopy

Philips’ solution uses real-time 3D imaging with augmented fluoroscopy to support high-accuracy diagnosis and minimally invasive therapy in a single room. The study results were published in the October 2021 issue of the Journal of Bronchology & Interventional Pulmonology: Volume 28 – Issue 4.

Bronchoscopy procedure performed with Philips Advanced Imaging

This Philips platform also offers promising prospects not only for diagnosing but also for immediately treating these lung cancer patients using new procedures such as tumor ablation.

Dr Kelvin Lau, Consultant and Chief Thoracic Surgeon at St Bartholomew’s Hospital, London, has successfully diagnosed and treated patients with lung cancer using cone beam computed tomography for biopsy, ablation microwave bronchoscopy, all in one procedure, during the initial clinical trial.

Advanced imaging with the Philips Lung Suite is used during procedures for real-time 3D image guidance and confirmation. Additional clinical trials at various hospitals are expected to begin soon.

All-in-one lung cancer diagnosis and treatment Philips Lung Suite provides all-in-one lung cancer diagnosis and treatment. It provides advanced real-time 3D imaging with augmented fluoroscopy on the company’s image-guided therapy system – Azurion, combined with dedicated software. With Philips Cone Beam CT imaging, the X-ray detector rotates around the patient to generate a CT-like image in approximately 5 seconds, providing clinicians with a high-resolution 3D view of the target lesion and other anatomical structures . This allows the clinician performing the biopsy procedure to be continuously guided by high quality, real-time imaging to advance a catheter to the lesion through a bronchoscope. Once done, its position can be confirmed in real time using the same imaging modality and a biopsy sample taken.

Philips offers a comprehensive portfolio of solutions for the diagnosis and treatment of lung cancer. In addition to Philips Lung Suite, the company’s Lung Cancer Orchestrator provides an integrated lung cancer patient management system for lung CT screening programs and lung incidental finding programs that manages and monitors patients at every step of their lung cancer screening and treatment decision journey. .

Several centers around the world have implemented this cutting-edge technology and innovated the procedure with the aim of shortening the patient journey, improving first-time diagnosis and reducing the overall cost of care.

“Philips aspires to transform lung cancer from a fatal disease to a managed disease, leaving no patient with early-stage lung cancer behind. Philips was there when heart surgery turned into the pose of coronary stent, and is here right now to drive that change for lung cancer patients,” said Elize Sturkenboom, Venture Leader IGT Lung Oncology.

Knowledge and technology are now available to diagnose and treat lung cancer earlier, more accurately and less invasively than ever before. Now is the time to move the needle and make a difference.




Warning: This is a commercial profile

© 2019. This work is under license CC-BY-NC-ND.

from the editor Recommended Articles


Comments are closed.